Emcure's Sanand oncology facility clears US FDA inspection with zero observations
Emcure Pharmaceuticals Limited announced that its oncology manufacturing facility in Sanand, Ahmedabad has successfully cleared a Pre-Approval Inspection (PAI) conducted by the US Food and Drug Administration (US FDA) without any observations.
In a regulatory filing on July 9, 2025, the company informed that the inspection was conducted between June 30 and July 8, 2025, and concluded without the issuance of a Form 483, indicating zero observations.
The Sanand facility is located at GIDC, Taluka Sanand, Ahmedabad, Gujarat, and specializes in the production of oncology products for regulated markets.
Emcure's Company Secretary & Compliance Officer, Chetan Sharma, signed the disclosure addressed to the National Stock Exchange of India and BSE Limited.
The company stated that the outcome of the inspection reflects its commitment to maintaining global quality and compliance standards.
For more details, visit: www.emcure.com
Disclaimer: The information provided in this article is based on the company's regulatory filing and is for informational purposes only. It does not constitute investment advice.
Ahmedabad Plane Crash
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
2 days ago
- Business Upturn
Kotak Mahindra Bank Q1 results: Net profit down 47% YoY to Rs 3,282 crore, GNPA at 1.48% vs 1.39% QoQ
Kotak Mahindra Bank reported a 47.5% year-on-year (YoY) decline in net profit for the quarter ended June 30, 2025, with Q1 FY26 profit standing at Rs 3,281.68 crore compared to Rs 6,249.82 crore in Q1 FY25. The sharp fall is primarily due to the absence of exceptional gains booked in the same quarter last year. Net Interest Income (NII) grew 6% YoY to Rs 7,259 crore from Rs 6,843 crore, reflecting steady growth in lending and core banking operations. Total income rose to Rs 16,916 crore from Rs 15,675 crore YoY. Operating profit (before provisions) rose to Rs 5,563.69 crore from Rs 5,254.11 crore in the previous year. Provisions and contingencies, however, jumped to Rs 1,207.76 crore from Rs 578.48 crore YoY, impacting the bank's profitability. Asset quality weakened slightly: Gross NPA: Rs 6,637.70 crore (1.48%) vs Rs 5,477.15 crore (1.39%) QoQ Net NPA: Rs 1,530.93 crore (0.34%) vs Rs 1,376.33 crore (0.35%) QoQ Despite steady growth in core income, the YoY profit decline was driven by the high base effect of last year's Rs 3,519.90 crore exceptional gain. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
2 days ago
- Business Upturn
Alembic Pharma gets USFDA nod for Carbamazepine Extended-Release Tablets
Alembic Pharmaceuticals Limited has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Carbamazepine Extended-Release Tablets USP in strengths of 100 mg, 200 mg, and 400 mg. These tablets are the generic version of Tegretol-XR, a widely used anticonvulsant drug developed by Novartis Pharmaceuticals. Alembic's version is therapeutically equivalent to the original, meaning it meets the same standards for quality, strength, and effectiveness. Carbamazepine Extended-Release Tablets are primarily used to treat seizure disorders and are also prescribed for trigeminal neuralgia, a chronic pain condition affecting the facial nerves. According to IQVIA data, the US market for this drug was valued at approximately $71 million for the 12-month period ending March 2025. With this approval, Alembic now has a total of 225 ANDA approvals from the USFDA, which includes 202 final approvals and 23 tentative approvals. About Alembic Pharmaceuticals Founded in 1907 and headquartered in India, Alembic Pharmaceuticals is a vertically integrated pharmaceutical company known for its strong focus on research and development. It manufactures and markets generic drugs across global markets, with several of its facilities approved by top regulatory bodies including the USFDA. In India, Alembic is a leader in branded generics, with a product portfolio promoted by a field force of over 5,500 professionals. Its products are widely recognized and trusted by healthcare professionals and patients alike. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
2 days ago
- Business Upturn
J&K Bank Q1 results: Net profit up 17% YoY to Rs 485 crore, NII grows 7%
Jammu & Kashmir Bank reported its #Q1Results with a strong performance in profitability and stable asset quality. The bank posted a net profit of Rs 484.84 crore for the April–June quarter of FY26, marking a 16.7% year-on-year increase from Rs 415.49 crore in Q1 FY25. The improvement came despite a one-time impairment provision of Rs 87 crore related to its investment in J&K Grameen Bank post-amalgamation. Without this impact, YoY profit growth would have exceeded 30%, the bank noted. Net interest income (NII) rose 7% to Rs 1,465 crore from Rs 1,369 crore, while other income jumped 29% to Rs 250 crore. Operating profit also saw a 13% rise, coming in at Rs 673 crore. Gross NPA improved to 3.50% YoY (though slightly up sequentially from 3.37%), while Net NPA remained stable at 0.82%. The NPA Coverage Ratio remained strong at above 90%. The bank's deposits grew 12% YoY to Rs 1.49 lakh crore, and net advances rose 6% to Rs 1.01 lakh crore. CASA ratio stood at 45.71%, while Return on Assets (RoA) improved to 1.17%. Capital Adequacy Ratio (CAR) was reported at 15.98%, giving the bank a strong buffer for future growth. MD & CEO Amitava Chatterjee stated the bank is witnessing improving ground conditions and remains focused on expanding Rest of India operations and digital capabilities. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
